{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:02:07Z","timestamp":1794002527644,"version":"4.8.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijantimicag.2022.106633","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T03:09:16Z","timestamp":1656644956000},"page":"106633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"title":["Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6413-3396","authenticated-orcid":false,"given":"Souha S.","family":"Kanj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattarachai","family":"Kiratisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Virginia","family":"Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4784-3227","authenticated-orcid":false,"given":"David","family":"van Duin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106633_bib0001","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_sbref0002","series-title":"Global priority list of antibiotics-resistant bacteria to guide research, discovery, and development of new antibiotics","year":"2017"},{"key":"10.1016\/j.ijantimicag.2022.106633_sbref0003","series-title":"Facility guidance for control of carbapenem-resistant Enterobacteriaceae\u2014November 2015 update","year":"2015"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0004","unstructured":"Centers for Disease Control. Antibiotic resistance threats in the United States, 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf [accessed 01 April 2021]."},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0005","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1021\/acsinfecdis.0c00026","article-title":"Innovation in Antimicrobial Resistance: The CARB-X Perspective","volume":"6","author":"Alm","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz089","article-title":"The Infectious Diseases Society of America's 10 x '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 x '20 a Possibility?","volume":"69","author":"Talbot","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0007","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41579-019-0288-0","article-title":"The global preclinical antibacterial pipeline","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0008","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of beta-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0009","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.idc.2016.02.007","article-title":"New beta-Lactamase Inhibitors in the Clinic","volume":"30","author":"Papp-Wallace","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0010","doi-asserted-by":"crossref","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","article-title":"New beta-Lactam-beta-Lactamase Inhibitor Combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0011","unstructured":"US Food and Drug Administration. Drug Trials Snapshot: AVYCAZ (cIAI), 2015. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshot-avycaz-ciai [accessed 06 August 2021]."},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02446-17","article-title":"Avibactam Pharmacokinetic\/Pharmacodynamic Targets","volume":"62","author":"Nichols","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0013","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0014","doi-asserted-by":"crossref","first-page":"ofaa651","DOI":"10.1093\/ofid\/ofaa651","article-title":"Meta-analysis of Clinical Outcomes Using Ceftazidime\/Avibactam, Ceftolozane\/Tazobactam, and Meropenem\/Vaborbactam for the Treatment of Multidrug-Resistant Gram-Negative Infections","volume":"8","author":"Wilson","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.idnow.2020.11.007","article-title":"The multiple benefits of second-generation beta-lactamase inhibitors in treatment of multidrug-resistant bacteria","author":"de Sousa Coelho","year":"2021","journal-title":"Infect Dis Now"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0016","doi-asserted-by":"crossref","first-page":"9308","DOI":"10.3390\/ijms21239308","article-title":"New Carbapenemase Inhibitors: Clearing the Way for the beta-Lactams","volume":"21","author":"Vazquez-Ucha","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0017","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a Cyclic Boronic Acid beta-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0018","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s10096-018-3260-4","article-title":"Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae","volume":"37","author":"Lee","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40121-020-00286-6","article-title":"Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms","volume":"9","author":"Wu","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpubh.2019.00151","article-title":"The \"Old\" and the \"New\" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How","volume":"7","author":"Karaiskos","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01726-20","volume":"65","author":"Yang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0022","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0023","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0024","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0025","unstructured":"Zaviceft a 2 g\/0.5g powder for concentrate for solutionfor infusion - summary of product characteristics, 2021. https:\/\/www.medicines.org.uk\/emc\/product\/2465 [accessed 06 August 2021]."},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0026","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0027","article-title":"Treating infections caused by carbapenemase-producing Enterobacterales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA Pharmacy Infection Network (PIN)","volume":"2","author":"Hughes","year":"2020","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0028","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-\u03b2-lactamase-Producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0029","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-018-0966-7","article-title":"Meropenem\/Vaborbactam: A Review in Complicated Urinary Tract Infections","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0030","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/QCO.0000000000000600","article-title":"The role of new beta-lactamase inhibitors in gram-negative infections","volume":"32","author":"Vena","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01694-17","article-title":"Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae","volume":"61","author":"Sun","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0032","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2334-10-72","article-title":"Comparative in vitro activity of Meropenem, Imipenem and Piperacillin\/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study","volume":"10","author":"Joly-Guillou","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0033","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/phar.2092","article-title":"Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae","volume":"38","author":"Jorgensen","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0034","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of Meropenem Combined with RPX7009, a Novel beta-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0035","article-title":"Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0036","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0037","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02177-19","article-title":"Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018","volume":"64","author":"Carvalhaes","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0038","first-page":"ciaa803","article-title":"Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem\/Cilastatin\/Relebactam Versus Piperacillin\/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)","author":"Titov","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0039","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0040","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/ajhp\/zxab012","article-title":"Imipenem\/cilastatin\/relebactam: A new carbapenem beta-lactamase inhibitor combination","volume":"78","author":"Mansour","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0041","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jiac.2020.09.032","article-title":"The safety and efficacy of relebactam\/imipenem\/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study","volume":"27","author":"Kohno","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0042","doi-asserted-by":"crossref","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0043","unstructured":"ZERBAXA\u00ae. Highlights of Prescribing Information. 2020. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zerbaxa\/zerbaxa_pi.pdf [accessed 22 April 2022]."},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0044","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0045","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0046","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0047","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/IDR.S180905","article-title":"Ceftolozane\/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy","volume":"12","author":"Escola-Verge","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0048","doi-asserted-by":"crossref","first-page":"dlaa129","DOI":"10.1093\/jacamr\/dlaa129","article-title":"Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU","volume":"3","author":"Moise","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0049","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/antibiotics9020061","article-title":"Carbapenem-Sparing Strategies for ESBL Producers: When and How","volume":"9","author":"Karaiskos","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0051","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0052","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0053","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0054","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/cid\/ciab295","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0055","unstructured":"Clinicaltrials.gov. NCT03869437. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03869437 [accessed 22 April 2022]."},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0056","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/cid\/civ020","article-title":"Extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat","volume":"60","author":"Lukac","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0057","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/trstmh\/trz125","article-title":"The burden of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Nigeria: a systematic review and meta-analysis","volume":"114","author":"Musa","year":"2020","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0058","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/14787210.6.5.671","article-title":"Clinical significance of extended-spectrum beta-lactamases","volume":"6","author":"Rodriguez-Bano","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0059","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.14822.1","article-title":"Treatment of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?","volume":"7","author":"Pana","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0060","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0061","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/jtm\/taw102","article-title":"The ecology of extended-spectrum beta-lactamases (ESBLs) in the developed world","volume":"24","author":"Doi","year":"2017","journal-title":"J Travel Med"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0062","doi-asserted-by":"crossref","first-page":"ofz353","DOI":"10.1093\/ofid\/ofz353","article-title":"Molecular Epidemiology of Ceftriaxone Non-Susceptible Enterobacterales Isolates in an Academic Medical Center in the United States","volume":"6","author":"Tamma","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.48.1.1-14.2004","article-title":"Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes","volume":"48","author":"Bonnet","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0064","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of beta-Lactamase-Producing Pathogens","volume":"33","author":"Bush","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0065","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0066","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0067","doi-asserted-by":"crossref","first-page":"dlaa112","DOI":"10.1093\/jacamr\/dlaa112","article-title":"CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales","volume":"3","author":"Rodriguez-Bano","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0068","first-page":"ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","author":"Henderson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0069","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/cid\/ciw741","article-title":"Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0070","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0071","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace","volume":"215","author":"Logan","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0072","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.diagmicrobio.2018.10.004","article-title":"Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016","volume":"93","author":"Senchyna","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0073","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.diagmicrobio.2017.07.013","article-title":"Review: Molecular detection of extended spectrum-beta-lactamase- and carbapenemase-producing Enterobacteriaceae in a clinical setting","volume":"89","author":"Rood","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0074","series-title":"Carbapenem Resistant Enterobacteriaceae","author":"Smith","year":"2021"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0075","first-page":"1","article-title":"Carbapenem Resistance: A Review","volume":"6","author":"Codjoe","year":"2017","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0076","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13756-016-0115-6","article-title":"Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia","volume":"5","author":"Suwantarat","year":"2016","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0077","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(16)30257-2","article-title":"Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study","volume":"17","author":"Grundmann","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0078","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.2015.12480","article-title":"Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013","volume":"314","author":"Guh","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0079","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0080","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.00064-16","article-title":"Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes","volume":"30","author":"Poirel","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0081","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0082","unstructured":"European Medicines Agency. Recommendations to restrict use of fosfomycin antibiotics EMA\/670563\/2019, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/recommendations-restrict-use-fosfomycin-antibiotics_en.pdf [accessed 24 May 2021]."},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0083","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/IJGM.S214305","article-title":"Carbapenem-Resistant Klebsiella pneumoniae: Microbiology Key Points for Clinical Practice","volume":"12","author":"Reyes","year":"2019","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0084","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fmicb.2019.00080","article-title":"Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options","volume":"10","author":"Sheu","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106633_sbref0085","series-title":"Acinetobacter in healthcare settings","year":"2019"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0086","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1086\/502205","article-title":"Acinetobacter outbreaks, 1977-2000","volume":"24","author":"Villegas","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0087","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1128\/AAC.01464-06","article-title":"Global challenge of multidrug-resistant Acinetobacter baumannii","volume":"51","author":"Perez","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0088","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/500202","article-title":"The epidemiology and control of Acinetobacter baumannii in health care facilities","volume":"42","author":"Fournier","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0089","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0248-2020","article-title":"Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings","volume":"53","author":"Kurihara","year":"2020","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0090","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0091","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0092","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.cmi.2019.03.014","article-title":"Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment","volume":"25","author":"Piperaki","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0093","doi-asserted-by":"crossref","first-page":"e01110","DOI":"10.1128\/AAC.01110-18","article-title":"New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections","volume":"63","author":"Isler","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0094","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/305784","article-title":"Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries","volume":"2014","author":"Djahmi","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0095","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1177\/0300060519864181","article-title":"Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study","volume":"47","author":"Terahara","year":"2019","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0096","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.614058","article-title":"Mobile Carbapenemase Genes in Pseudomonas aeruginosa","volume":"12","author":"Yoon","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0097","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/AAC.02379-15","article-title":"Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-beta-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"60","author":"Kazmierczak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0098","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1128\/AAC.03056-15","article-title":"In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014","volume":"60","author":"Huband","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0099","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijantimicag.2014.01.007","article-title":"Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012","volume":"43","author":"Sader","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0100","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/249856","article-title":"Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria","volume":"2014","author":"Dortet","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0101","doi-asserted-by":"crossref","DOI":"10.1128\/mSystems.00787-21","article-title":"Emergence of Ceftazidime- and Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Pseudomonas aeruginosa in China","volume":"6","author":"Zhu","year":"2021","journal-title":"mSystems"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0102","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/emi.2016.22","article-title":"Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies","volume":"5","author":"Zhang","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0103","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212527","article-title":"How to manage Pseudomonas aeruginosa infections","volume":"7","author":"Bassetti","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0104","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003495-200767030-00003","article-title":"The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections","volume":"67","author":"Driscoll","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.diagmicrobio.2017.06.017","article-title":"Risk factors for carbapenem-nonsusceptible Pseudomonas aeruginosa: Case-control study","volume":"89","author":"Khadem","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0106","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0107","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/eri.09.108","article-title":"Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy","volume":"8","author":"Zavascki","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0108","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0109","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0110","doi-asserted-by":"crossref","first-page":"ofz522","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections","volume":"6","author":"Jorgensen","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0111","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-018-1133-5","article-title":"Ceftolozane\/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections","volume":"46","author":"Escola-Verge","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0112","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter Evaluation of Ceftolozane\/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0113","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jgar.2018.01.010","article-title":"Clinical experience with ceftolozane\/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa","volume":"13","author":"Xipell","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0114","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fmed.2019.00074","article-title":"Treatment of Infections Due to MDR Gram-Negative Bacteria","volume":"6","author":"Bassetti","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0116","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0117","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem\/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0118","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0119","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/antibiotics9040196","article-title":"Trends, Epidemiology, and Management of Multi-Drug Resistant Gram-Negative Bacterial Infections in the Hospitalized Setting","volume":"9","author":"Morris","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0120","unstructured":"US Department of Health and Human Services Centre for Disease Control. Multidrug-resistant Pseudomonas aeruginosa AR Threats Report, 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/pseudomonas-aeruginosa-508.pdf [accessed 30 October 2021]."},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0121","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.3390\/ijms22063128","article-title":"Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors","volume":"22","author":"Jurado-Martin","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0122","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.3390\/ijerph10126235","article-title":"Escherichia coli in Europe: an overview","volume":"10","author":"Allocati","year":"2013","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0123","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/phar.1636","article-title":"Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management","volume":"35","author":"Kaye","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0124","series-title":"Gram Negative Bacteria","author":"Oliveira","year":"2021"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0125","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/clinids\/10.4.850","article-title":"Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies","volume":"10","author":"Sirot","year":"1988","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0126","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0127","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3389\/fmicb.2015.00392","article-title":"Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment","volume":"6","author":"Davin-Regli","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0128","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0140-6736(17)33296-8","article-title":"Shigellosis","volume":"391","author":"Kotloff","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0129","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jiph.2017.09.025","article-title":"Emergence of antibiotic resistant Shigella species: A matter of concern","volume":"11","author":"Puzari","year":"2018","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0130","unstructured":"US Department of Health and Human Services Centers for Desease Control and Prevention. Drug-resistant Salmonella serotype typhi, 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/salmonella-typhi-508.pdf [accessed 01 November 2021]."},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0131","unstructured":"US Department of Health and Human Services Centers for Disease Control and Prevention. Drug-resistant nontyphoidal Salmonella, 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/nt-salmonella-508.pdf [accessed 01 November 2021]."},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0132","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MOG.0000000000000406","article-title":"The evolution of antimicrobial resistance in Salmonella typhi","volume":"34","author":"Karkey","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"10.1016\/j.ijantimicag.2022.106633_bib0133","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.ARBA-0014-2017","article-title":"Antimicrobial Resistance in Nontyphoidal Salmonella","volume":"6","author":"McDermott","year":"2018","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.ijantimicag.2022.106633_bib0134","doi-asserted-by":"crossref","DOI":"10.1128\/ecosalplus.esp-0009-2017","article-title":"Pathogenesis of Proteus mirabilis Infection","volume":"8","author":"Armbruster","year":"2018","journal-title":"EcoSal Plus"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0135","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00085-17","article-title":"Proteus spp. as Putative Gastrointestinal Pathogens","volume":"31","author":"Hamilton","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0136","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party","volume":"73","author":"Hawkey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0137","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1101\/gr.205245.116","article-title":"Recent independent emergence of multiple multidrug-resistant Serratia marcescens clones within the United Kingdom and Ireland","volume":"26","author":"Moradigaravand","year":"2016","journal-title":"Genome Res"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0138","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0924-8579(02)00163-2","article-title":"Natural antibiotic susceptibility of strains of Serratia marcescens and the S. liquefaciens complex: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii","volume":"22","author":"Stock","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0139","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/5584_2019_367","article-title":"Current and Future Treatment of Helicobacter pylori Infections","volume":"1149","author":"Matsumoto","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.ijantimicag.2022.106633_bib0140","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.ARBA-0013-2017","article-title":"Antimicrobial Resistance in Campylobacter spp","volume":"6","author":"Shen","year":"2018","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0141","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12866-020-01785-9","article-title":"Extensively drug-resistant Haemophilus influenzae - emergence, epidemiology, risk factors, and regimen","volume":"20","author":"Su","year":"2020","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0142","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00430-019-00651-4","article-title":"Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century","volume":"209","author":"Mlynarczyk-Bonikowska","year":"2020","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0143","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0144","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: Second-generation \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106633_bib0145","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1060028020929988","article-title":"Cefiderocol: A Siderophore Cephalosporin","volume":"54","author":"El-Lababidi","year":"2020","journal-title":"Ann Pharmacother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:44:31Z","timestamp":1760377471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":145,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0924857922001455"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106633","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106633"}}